Competitive Advantages:
Novel method for treatment of various chronic lung diseases, Help screen lung microbiome of healthy donors, Amplification of an otherwise limited resource.
Disclosed herein is a method to isolate and cultivate the lung microbiome obtained from bronchoalveolar lavage. The disclosed method involves lung microbiome culturomics based on three different media for both aerobic and fastidious anaerobic bacteria. The disclosed method allows for amplification of the lung microbiome, which can be used, for example, for subsequent testing of antibiotic sensitivity, drug resistance, or for lung microbiome transplantation. Chronic lung diseases such as asthma, COPD, cystic fibrosis, or lung transplant patients critically depend on a beneficial lung microbiome as part of the healing process and/or to revert their chronic lung disease. Hence the favorable modulation of lung microbiota obtained from healthy donors may impact the host immune response to reduce progression of lung diseases. Since the microbiome of the lung has relatively less bacterial biomass when compared to the lower gastrointestinal tract it is difficult to obtain sufficient quantities of lung microbiome samples for direct clinical analysis. Researchers at the University of South Florida have developed a procedure for the isolation and cultivation of lung microbiome from patients with chronic lung diseases. Bronchoalveolar lavage was used to isolate and subsequently cultivate and amplify the lung microbiome from patients based on three different media that allow the growth of aerobic and fastidious anaerobic lung bacteria. This novel procedure to isolate, cultivate, and amplify the lung microbiome of patients to sufficient quantities can have several applications, including microbiome testing in a clinical laboratory setting, antibiotic sensitivity testing, drug resistance testing, and amplification and transplantation of naturally occurring lung microbiome
Brochure
